

William Y Kim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1399856/publications.pdf>

Version: 2024-02-01

64
papers

9,486
citations

94269

37
h-index

114278

63
g-index

67
all docs

67
docs citations

67
times ranked

14291
citing authors

#	ARTICLE	IF	CITATIONS
1	The Regulation of INK4/ARF in Cancer and Aging. <i>Cell</i> , 2006, 127, 265-275.	13.5	885
2	Role of VHL Gene Mutation in Human Cancer. <i>Journal of Clinical Oncology</i> , 2004, 22, 4991-5004.	0.8	874
3	A Consensus Molecular Classification of Muscle-invasive Bladder Cancer. <i>European Urology</i> , 2020, 77, 420-433.	0.9	741
4	Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2014, 111, 3110-3115.	3.3	736
5	Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy. <i>European Urology</i> , 2017, 72, 544-554.	0.9	638
6	Dynamic Reprogramming of the Kinome in Response to Targeted MEK Inhibition in Triple-Negative Breast Cancer. <i>Cell</i> , 2012, 149, 307-321.	13.5	637
7	Inhibition of HIF2 β Is Sufficient to Suppress pVHL-Defective Tumor Growth. <i>PLoS Biology</i> , 2003, 1, e83.	2.6	516
8	The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. <i>Cancer Cell</i> , 2006, 9, 485-495.	7.7	427
9	Coexistent ARID1A and PIK3CA mutations promote ovarian clear-cell tumorigenesis through pro-tumorigenic inflammatory cytokine signalling. <i>Nature Communications</i> , 2015, 6, 6118.	5.8	247
10	VHL Promotes E2 Box-Dependent E-Cadherin Transcription by HIF-Mediated Regulation of SIP1 and Snail. <i>Molecular and Cellular Biology</i> , 2007, 27, 157-169.	1.1	230
11	Integrative Genomic and Proteomic Analyses Identify Targets for Lkb1-Deficient Metastatic Lung Tumors. <i>Cancer Cell</i> , 2010, 17, 547-559.	7.7	215
12	Failure to prolyl hydroxylate hypoxia-inducible factor β phenocopies VHL inactivation in vivo. <i>EMBO Journal</i> , 2006, 25, 4650-4662.	3.5	210
13	Endogenous retroviral signatures predict immunotherapy response in clear cell renal cell carcinoma. <i>Journal of Clinical Investigation</i> , 2018, 128, 4804-4820.	3.9	210
14	Bladder Cancer Molecular Taxonomy: Summary from a Consensus Meeting. <i>Bladder Cancer</i> , 2016, 2, 37-47.	0.2	184
15	Claudin-low bladder tumors are immune infiltrated and actively immune suppressed. <i>JCI Insight</i> , 2016, 1, e85902.	2.3	179
16	The von Hippel-Lindau tumor suppressor protein: new insights into oxygen sensing and cancer. <i>Current Opinion in Genetics and Development</i> , 2003, 13, 55-60.	1.5	170
17	Targeting Tumor-Associated Fibroblasts for Therapeutic Delivery in Desmoplastic Tumors. <i>Cancer Research</i> , 2017, 77, 719-731.	0.4	169
18	pVHL Acts as an Adaptor to Promote the Inhibitory Phosphorylation of the NF- κ B Agonist Card9 by CK2. <i>Molecular Cell</i> , 2007, 28, 15-27.	4.5	163

#	ARTICLE	IF	CITATIONS
19	The Binding Site Barrier Elicited by Tumor-Associated Fibroblasts Interferes Disposition of Nanoparticles in Stroma-Vessel Type Tumors. <i>ACS Nano</i> , 2016, 10, 9243-9258.	7.3	161
20	State of the Science: An Update on Renal Cell Carcinoma. <i>Molecular Cancer Research</i> , 2012, 10, 859-880.	1.5	142
21	VHL substrate transcription factor ZHX2 as an oncogenic driver in clear cell renal cell carcinoma. <i>Science</i> , 2018, 361, 290-295.	6.0	134
22	HIF1 α and HIF2 α independently activate SRC to promote melanoma metastases. <i>Journal of Clinical Investigation</i> , 2013, 123, 2078-2093.	3.9	132
23	HIF2 α cooperates with RAS to promote lung tumorigenesis in mice. <i>Journal of Clinical Investigation</i> , 2009, 119, 2160-2170.	3.9	129
24	Identification of Clonal Hematopoiesis Mutations in Solid Tumor Patients Undergoing Unpaired Next-Generation Sequencing Assays. <i>Clinical Cancer Research</i> , 2018, 24, 5918-5924.	3.2	84
25	Molecular Subtype-Specific Immunocompetent Models of High-Grade Urothelial Carcinoma Reveal Differential Neoantigen Expression and Response to Immunotherapy. <i>Cancer Research</i> , 2018, 78, 3954-3968.	0.4	82
26	Fibroblast growth factor receptor 3 alterations and response to immune checkpoint inhibition in metastatic urothelial cancer: a real world experience. <i>British Journal of Cancer</i> , 2021, 125, 1251-1260.	2.9	77
27	Two sides to every story: the HIF-dependent and HIF-independent functions of pVHL. <i>Journal of Cellular and Molecular Medicine</i> , 2011, 15, 187-195.	1.6	76
28	Immuno-PET imaging of tumor-infiltrating lymphocytes using zirconium-89 radiolabeled anti-CD3 antibody in immune-competent mice bearing syngeneic tumors. <i>PLoS ONE</i> , 2018, 13, e0193832.	1.1	74
29	Phase II Study of Gemcitabine and Split-Dose Cisplatin Plus Pembrolizumab as Neoadjuvant Therapy Before Radical Cystectomy in Patients With Muscle-Invasive Bladder Cancer. <i>Journal of Clinical Oncology</i> , 2021, 39, 3140-3148.	0.8	72
30	MYC activation cooperates with Vhl and Ink4a/Arf loss to induce clear cell renal cell carcinoma. <i>Nature Communications</i> , 2017, 8, 15770.	5.8	64
31	HIF, hypoxia and the role of angiogenesis in non-small cell lung cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2010, 14, 1047-1057.	1.5	63
32	Molecular Pathways in Renal Cell Carcinoma—Rationale for Targeted Treatment. <i>Seminars in Oncology</i> , 2006, 33, 588-595.	0.8	62
33	Intrinsic Genomic Differences Between African American and White Patients With Clear Cell Renal Cell Carcinoma. <i>JAMA Oncology</i> , 2016, 2, 664.	3.4	54
34	Erythropoietin promotes breast tumorigenesis through tumor-initiating cell self-renewal. <i>Journal of Clinical Investigation</i> , 2014, 124, 553-563.	3.9	53
35	mTOR pathway in renal cell carcinoma. <i>Expert Review of Anticancer Therapy</i> , 2008, 8, 283-292.	1.1	48
36	Entinostat induces antitumor immune responses through immune editing of tumor neoantigens. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	43

#	ARTICLE	IF	CITATIONS
37	Targeting Tumor Hypoxia With Hypoxia-Activated Prodrugs. <i>Journal of Clinical Oncology</i> , 2015, 33, 1505-1508.	0.8	41
38	Genome-wide Screening Identifies SFMBT1 as an Oncogenic Driver in Cancer with VHL Loss. <i>Molecular Cell</i> , 2020, 77, 1294-1306.e5.	4.5	41
39	Mouse Reporter Strain for Noninvasive Bioluminescent Imaging of Cells that have Undergone Cre-Mediated Recombination. <i>Molecular Imaging</i> , 2003, 2, 153535002003031.	0.7	36
40	Racial disparities in survival among patients with advanced renal cell carcinoma in the targeted therapy era. <i>Cancer</i> , 2016, 122, 2988-2995.	2.0	32
41	<i>Sav1</i> Loss Induces Senescence and Stat3 Activation Coinciding with Tubulointerstitial Fibrosis. <i>Molecular and Cellular Biology</i> , 2017, 37, .	1.1	29
42	Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. <i>British Journal of Cancer</i> , 2018, 119, 801-807.	2.9	29
43	Effect of Cisplatin and Gemcitabine With or Without Berzosertib in Patients With Advanced Urothelial Carcinoma. <i>JAMA Oncology</i> , 2021, 7, 1536.	3.4	28
44	Pparg signaling controls bladder cancer subtype and immune exclusion. <i>Nature Communications</i> , 2021, 12, 6160.	5.8	28
45	Identification of a Novel Inflamed Tumor Microenvironment Signature as a Predictive Biomarker of Bacillus Calmette-Guérin Immunotherapy in Non-muscle-Invasive Bladder Cancer. <i>Clinical Cancer Research</i> , 2021, 27, 4599-4609.	3.2	26
46	MERTK mediated novel site Akt phosphorylation alleviates SAV1 suppression. <i>Nature Communications</i> , 2019, 10, 1515.	5.8	25
47	ZHX2 promotes HIF1 α oncogenic signaling in triple-negative breast cancer. <i>ELife</i> , 2021, 10, .	2.8	21
48	mTOR Inhibition Induces Compensatory, Therapeutically Targetable MEK Activation in Renal Cell Carcinoma. <i>PLoS ONE</i> , 2014, 9, e104413.	1.1	20
49	Neoadjuvant docetaxel/estramustine prior to radical prostatectomy or external beam radiotherapy in high risk localized prostate cancer: A phase II trial. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2011, 29, 608-613.	0.8	15
50	Neoadjuvant chemotherapy administration and time to cystectomy for muscle-invasive bladder cancer: An evaluation of transitions between academic and community settings. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2015, 33, 386.e1-386.e6.	0.8	15
51	Pilot Study of [18F] Fluorodeoxyglucose Positron Emission Tomography (FDG-PET)/Magnetic Resonance Imaging (MRI) for Staging of Muscle-invasive Bladder Cancer (MIBC). <i>Clinical Genitourinary Cancer</i> , 2020, 18, 378-386.e1.	0.9	15
52	Drug Efficacy Testing in Mice. <i>Current Topics in Microbiology and Immunology</i> , 2010, 355, 19-38.	0.7	14
53	Age at diagnosis, obesity, smoking, and molecular subtypes in muscle-invasive bladder cancer. <i>Cancer Causes and Control</i> , 2017, 28, 539-544.	0.8	14
54	RNA Expression Profiling of Lymphoepithelioma-Like Carcinoma of the Bladder Reveals a Basal-Like Molecular Subtype. <i>American Journal of Pathology</i> , 2020, 190, 134-144.	1.9	13

#	ARTICLE	IF	CITATIONS
55	PBRM1 Inactivation Promotes Upregulation of Human Endogenous Retroviruses in a HIF-Dependent Manner. <i>Cancer Immunology Research</i> , 2022, 10, 285-290.	1.6	13
56	Stearoyl Co-A Desaturase 1 as a ccRCC Therapeutic Target: Death by Stress. <i>Clinical Cancer Research</i> , 2013, 19, 3111-3113.	3.2	12
57	Neoadjuvant pazopanib and molecular analysis of tissue response in renal cell carcinoma. <i>JCI Insight</i> , 2020, 5, .	2.3	11
58	VHL Inactivation: A New Road to Senescence. <i>Cancer Cell</i> , 2008, 13, 295-297.	7.7	8
59	Roadmap for the development of the University of North Carolina at Chapel Hill Genitourinary Oncology Databaseâ€”UNC GOLD. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2014, 32, 32.e1-32.e9.	0.8	8
60	RAF1 amplification: an exemplar of MAPK pathway activation in urothelial carcinoma. <i>Journal of Clinical Investigation</i> , 2021, 131, .	3.9	6
61	The Geriatrics and Genetics behind Bladder Cancer. <i>American Society of Clinical Oncology Educational Book / ASCO American Society of Clinical Oncology Meeting</i> , 2014, , e192-e195.	1.8	3
62	Reply To Kenneth B. Yatai, Mark J. Dunning, Dennis Wang. Consensus Genomic Subtypes of Muscle-invasive Bladder Cancer: A Step in the Right Direction but Still a Long Way To Go. <i>Eur Urol</i> 2020;77:434â€”5. <i>European Urology</i> , 2020, 77, 436-438.	0.9	1
63	A bipartite graph-based expected networks approach identifies DDR genes not associated with TMB yet predictive of immune checkpoint blockade response. <i>Cell Reports Medicine</i> , 2022, 3, 100602.	3.3	1
64	Molecular responses to hypoxia: ancient pathways, clinical promises. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 2757-2758.	1.6	0